Jim Glasheen, PhD is the Executive Vice Chancellor for Innovation & Business Development at UMass Medical School, a position in which he leads a comprehensive and strategic approach to strengthening the scope and impact of the medical school’s biomedical research enterprise, which currently exceeds $250 million in annual external funding; and leveraging the commercialization of our IP portfolio through alliances, collaborations, agreements and partnerships with new and established life sciences partners. Dr. Glasheen was previously a general partner at Technology Partners, a venture capital fund in California. Companies in which he was an investor and/or board member include: Cadence Pharmaceuticals (CADX then acquired by Mallinckrodt), Revance Therapeutics (RVNC), Iomai (IOMI then acquired by Intercell), Incline Therapeutics (acquired by The Medicines Company), Transcend Medical (acquired by Novartis), Vision 5 (acquired by Allergan), Corcept (CORT), and Elcelyx (private). Glasheen is also the co-founder and co-chairman of the ConsumerMed, a non-profit organization focused on patient-centered health. Prior to his venture career, he was a consultant with McKinsey and Company and was a leader within their Pharmaceuticals and Medical Products practice. He is a graduate of Duke University and Harvard University, where he received a PhD in biology, followed by a postdoctoral fellowship at the University of California Berkeley.